Howard I. Scher
Defined how prostate cancer trials are run and read, from PSA working-group criteria to circulating tumour cell biomarkers.
Led the Prostate Cancer Clinical Trials Working Group criteria used across the field, and the Prostate Cancer Foundation clinical trials consortium. Showed that AR-V7 in circulating tumour cells predicts resistance to abiraterone and enzalutamide.
| Title | Journal | Year |
|---|---|---|
| Increased survival with enzalutamide in prostate cancer after chemotherapy | New England Journal of Medicine | 2012 |
| Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer | JAMA Oncology | 2016 |
Pages like this
not linked directly; found by shared links- CollectionProstate Cancer Foundation (PCF)
Shares Stand Up To Cancer, Enzalutamide, Abiraterone acetate, Androgen receptor.
- PersonCharles L. Sawyers
Shares Stand Up To Cancer, Enzalutamide, Androgen receptor, Memorial Sloan Kettering Cancer Center.
- TrialARCHES
Shares Enzalutamide, Prostate cancer.
- TermAndrogen receptor pathway inhibitor (ARPI)
Shares Enzalutamide, Abiraterone acetate, Androgen receptor, Prostate cancer.
- TrialEMBARK
Shares Enzalutamide, Prostate cancer.
- TrialPROpel
Shares Abiraterone acetate, Prostate cancer.
- TrialMAGNITUDE
Shares Abiraterone acetate, Prostate cancer.
- PersonRobert A. Gatenby
Shares Abiraterone acetate, Prostate cancer.